Recent News

• 03.04.2025 - GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication
• 02.24.2025 - Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols
• 02.18.2025 - GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
• 02.13.2025 - GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
• 02.12.2025 - GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
• 02.10.2025 - GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
• 02.10.2025 - GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

Recent Filings

• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 144 Report of proposed sale of securities
• 02.24.2025 - 144 Report of proposed sale of securities
• 02.21.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.20.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.20.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 02.20.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.20.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 02.20.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 02.18.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership